Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Neuropathic Pain Drugs Revenue 1.4 Market Analysis by Type 1.4.1 Global Neuropathic Pain Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Tricyclic Anti-Depressants Anticonvulsants 1.4.3 Serotonin-Norepinephrine Reuptake Inhibitor 1.4.4 Capsaicin Cream 1.4.5 Local Anaesthesia 1.4.6 Opioids 1.4.7 Steroids 1.4.8 Others 1.5 Market by Application 1.5.1 Global Neuropathic Pain Drugs Market Share by Application: 2020 VS 2026 1.5.2 Hospital Pharmacies 1.5.3 Retail Pharmacies 1.5.4 Online Pharmacies 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Neuropathic Pain Drugs Market Perspective (2015-2026) 2.2 Neuropathic Pain Drugs Growth Trends by Regions 2.2.1 Neuropathic Pain Drugs Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Neuropathic Pain Drugs Historic Market Share by Regions (2015-2020) 2.2.3 Neuropathic Pain Drugs Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Neuropathic Pain Drugs Market Growth Strategy 2.3.6 Primary Interviews with Key Neuropathic Pain Drugs Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Neuropathic Pain Drugs Players by Market Size 3.1.1 Global Top Neuropathic Pain Drugs Players by Revenue (2015-2020) 3.1.2 Global Neuropathic Pain Drugs Revenue Market Share by Players (2015-2020) 3.1.3 Global Neuropathic Pain Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Neuropathic Pain Drugs Market Concentration Ratio 3.2.1 Global Neuropathic Pain Drugs Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Drugs Revenue in 2019 3.3 Neuropathic Pain Drugs Key Players Head office and Area Served 3.4 Key Players Neuropathic Pain Drugs Product Solution and Service 3.5 Date of Enter into Neuropathic Pain Drugs Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Neuropathic Pain Drugs Historic Market Size by Type (2015-2020) 4.2 Global Neuropathic Pain Drugs Forecasted Market Size by Type (2021-2026) 5 Neuropathic Pain Drugs Breakdown Data by Application (2015-2026) 5.1 Global Neuropathic Pain Drugs Market Size by Application (2015-2020) 5.2 Global Neuropathic Pain Drugs Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Neuropathic Pain Drugs Market Size (2015-2020) 6.2 Neuropathic Pain Drugs Key Players in North America (2019-2020) 6.3 North America Neuropathic Pain Drugs Market Size by Type (2015-2020) 6.4 North America Neuropathic Pain Drugs Market Size by Application (2015-2020) 7 Europe 7.1 Europe Neuropathic Pain Drugs Market Size (2015-2020) 7.2 Neuropathic Pain Drugs Key Players in Europe (2019-2020) 7.3 Europe Neuropathic Pain Drugs Market Size by Type (2015-2020) 7.4 Europe Neuropathic Pain Drugs Market Size by Application (2015-2020) 8 China 8.1 China Neuropathic Pain Drugs Market Size (2015-2020) 8.2 Neuropathic Pain Drugs Key Players in China (2019-2020) 8.3 China Neuropathic Pain Drugs Market Size by Type (2015-2020) 8.4 China Neuropathic Pain Drugs Market Size by Application (2015-2020) 9 Japan 9.1 Japan Neuropathic Pain Drugs Market Size (2015-2020) 9.2 Neuropathic Pain Drugs Key Players in Japan (2019-2020) 9.3 Japan Neuropathic Pain Drugs Market Size by Type (2015-2020) 9.4 Japan Neuropathic Pain Drugs Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Neuropathic Pain Drugs Market Size (2015-2020) 10.2 Neuropathic Pain Drugs Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Neuropathic Pain Drugs Market Size by Type (2015-2020) 10.4 Southeast Asia Neuropathic Pain Drugs Market Size by Application (2015-2020) 11 India 11.1 India Neuropathic Pain Drugs Market Size (2015-2020) 11.2 Neuropathic Pain Drugs Key Players in India (2019-2020) 11.3 India Neuropathic Pain Drugs Market Size by Type (2015-2020) 11.4 India Neuropathic Pain Drugs Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Neuropathic Pain Drugs Market Size (2015-2020) 12.2 Neuropathic Pain Drugs Key Players in Central & South America (2019-2020) 12.3 Central & South America Neuropathic Pain Drugs Market Size by Type (2015-2020) 12.4 Central & South America Neuropathic Pain Drugs Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Neuropathic Pain Drugs Introduction 13.1.4 Pfizer Revenue in Neuropathic Pain Drugs Business (2015-2020)) 13.1.5 Pfizer Recent Development 13.2 Johnson & Johnson 13.2.1 Johnson & Johnson Company Details 13.2.2 Johnson & Johnson Business Overview and Its Total Revenue 13.2.3 Johnson & Johnson Neuropathic Pain Drugs Introduction 13.2.4 Johnson & Johnson Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.2.5 Johnson & Johnson Recent Development 13.3 Sanofi 13.3.1 Sanofi Company Details 13.3.2 Sanofi Business Overview and Its Total Revenue 13.3.3 Sanofi Neuropathic Pain Drugs Introduction 13.3.4 Sanofi Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.3.5 Sanofi Recent Development 13.4 GlaxoSmithKline 13.4.1 GlaxoSmithKline Company Details 13.4.2 GlaxoSmithKline Business Overview and Its Total Revenue 13.4.3 GlaxoSmithKline Neuropathic Pain Drugs Introduction 13.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.4.5 GlaxoSmithKline Recent Development 13.5 Eli Lilly 13.5.1 Eli Lilly Company Details 13.5.2 Eli Lilly Business Overview and Its Total Revenue 13.5.3 Eli Lilly Neuropathic Pain Drugs Introduction 13.5.4 Eli Lilly Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.5.5 Eli Lilly Recent Development 13.6 Bristol-Myers Squibb 13.6.1 Bristol-Myers Squibb Company Details 13.6.2 Bristol-Myers Squibb Business Overview and Its Total Revenue 13.6.3 Bristol-Myers Squibb Neuropathic Pain Drugs Introduction 13.6.4 Bristol-Myers Squibb Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.6.5 Bristol-Myers Squibb Recent Development 13.7 Biogen 13.7.1 Biogen Company Details 13.7.2 Biogen Business Overview and Its Total Revenue 13.7.3 Biogen Neuropathic Pain Drugs Introduction 13.7.4 Biogen Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.7.5 Biogen Recent Development 13.8 Baxter Healthcare 13.8.1 Baxter Healthcare Company Details 13.8.2 Baxter Healthcare Business Overview and Its Total Revenue 13.8.3 Baxter Healthcare Neuropathic Pain Drugs Introduction 13.8.4 Baxter Healthcare Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.8.5 Baxter Healthcare Recent Development 13.9 Depomed 13.9.1 Depomed Company Details 13.9.2 Depomed Business Overview and Its Total Revenue 13.9.3 Depomed Neuropathic Pain Drugs Introduction 13.9.4 Depomed Revenue in Neuropathic Pain Drugs Business (2015-2020) 13.9.5 Depomed Recent Development 14 Analyst's Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Neuropathic Pain Drugs Key Market Segments Table 2. Key Players Covered: Ranking by Neuropathic Pain Drugs Revenue Table 3. Ranking of Global Top Neuropathic Pain Drugs Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Neuropathic Pain Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Tricyclic Anti-Depressants Anticonvulsants Table 6. Key Players of Serotonin-Norepinephrine Reuptake Inhibitor Table 7. Key Players of Capsaicin Cream Table 8. Key Players of Local Anaesthesia Table 9. Key Players of Opioids Table 10. Key Players of Steroids Table 11. Key Players of Others Table 12. Global Neuropathic Pain Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 13. Global Neuropathic Pain Drugs Market Size by Regions (US$ Million): 2020 VS 2026 Table 14. Global Neuropathic Pain Drugs Market Size by Regions (2015-2020) (US$ Million) Table 15. Global Neuropathic Pain Drugs Market Share by Regions (2015-2020) Table 16. Global Neuropathic Pain Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 17. Global Neuropathic Pain Drugs Market Share by Regions (2021-2026) Table 18. Market Top Trends Table 19. Key Drivers: Impact Analysis Table 20. Key Challenges Table 21. Neuropathic Pain Drugs Market Growth Strategy Table 22. Main Points Interviewed from Key Neuropathic Pain Drugs Players Table 23. Global Neuropathic Pain Drugs Revenue by Players (2015-2020) (Million US$) Table 24. Global Neuropathic Pain Drugs Market Share by Players (2015-2020) Table 25. Global Top Neuropathic Pain Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuropathic Pain Drugs as of 2019) Table 26. Global Neuropathic Pain Drugs by Players Market Concentration Ratio (CR5 and HHI) Table 27. Key Players Headquarters and Area Served Table 28. Key Players Neuropathic Pain Drugs Product Solution and Service Table 29. Date of Enter into Neuropathic Pain Drugs Market Table 30. Mergers & Acquisitions, Expansion Plans Table 31. Global Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 32. Global Neuropathic Pain Drugs Market Size Share by Type (2015-2020) Table 33. Global Neuropathic Pain Drugs Revenue Market Share by Type (2021-2026) Table 34. Global Neuropathic Pain Drugs Market Size Share by Application (2015-2020) Table 35. Global Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 36. Global Neuropathic Pain Drugs Market Size Share by Application (2021-2026) Table 37. North America Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 38. North America Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 39. North America Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 40. North America Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 41. North America Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 42. North America Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 43. Europe Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 44. Europe Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 45. Europe Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 46. Europe Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 47. Europe Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 48. Europe Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 49. China Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 50. China Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 51. China Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 52. China Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 53. China Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 54. China Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 55. Japan Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 56. Japan Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 57. Japan Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 58. Japan Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 59. Japan Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 60. Japan Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 61. Southeast Asia Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 62. Southeast Asia Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 63. Southeast Asia Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 64. Southeast Asia Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 65. Southeast Asia Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 66. Southeast Asia Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 67. India Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 68. India Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 69. India Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 70. India Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 71. India Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 72. India Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 73. Central & South America Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$) Table 74. Central & South America Key Players Neuropathic Pain Drugs Market Share (2019-2020) Table 75. Central & South America Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$) Table 76. Central & South America Neuropathic Pain Drugs Market Share by Type (2015-2020) Table 77. Central & South America Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$) Table 78. Central & South America Neuropathic Pain Drugs Market Share by Application (2015-2020) Table 79. Pfizer Company Details Table 80. Pfizer Business Overview Table 81. Pfizer Product Table 82. Pfizer Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 83. Pfizer Recent Development Table 84. Johnson & Johnson Company Details Table 85. Johnson & Johnson Business Overview Table 86. Johnson & Johnson Product Table 87. Johnson & Johnson Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 88. Johnson & Johnson Recent Development Table 89. Sanofi Company Details Table 90. Sanofi Business Overview Table 91. Sanofi Product Table 92. Sanofi Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 93. Sanofi Recent Development Table 94. GlaxoSmithKline Company Details Table 95. GlaxoSmithKline Business Overview Table 96. GlaxoSmithKline Product Table 97. GlaxoSmithKline Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 98. GlaxoSmithKline Recent Development Table 99. Eli Lilly Company Details Table 100. Eli Lilly Business Overview Table 101. Eli Lilly Product Table 102. Eli Lilly Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 103. Eli Lilly Recent Development Table 104. Bristol-Myers Squibb Company Details Table 105. Bristol-Myers Squibb Business Overview Table 106. Bristol-Myers Squibb Product Table 107. Bristol-Myers Squibb Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 108. Bristol-Myers Squibb Recent Development Table 109. Biogen Company Details Table 110. Biogen Business Overview Table 111. Biogen Product Table 112. Biogen Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 113. Biogen Recent Development Table 114. Baxter Healthcare Business Overview Table 115. Baxter Healthcare Product Table 116. Baxter Healthcare Company Details Table 117. Baxter Healthcare Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 118. Baxter Healthcare Recent Development Table 119. Depomed Company Details Table 120. Depomed Business Overview Table 121. Depomed Product Table 122. Depomed Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$) Table 123. Depomed Recent Development Table 124. Research Programs/Design for This Report Table 125. Key Data Information from Secondary Sources Table 126. Key Data Information from Primary Sources List of Figures Figure 1. Global Neuropathic Pain Drugs Market Share by Type: 2020 VS 2026 Figure 2. Tricyclic Anti-Depressants Anticonvulsants Features Figure 3. Serotonin-Norepinephrine Reuptake Inhibitor Features Figure 4. Capsaicin Cream Features Figure 5. Local Anaesthesia Features Figure 6. Opioids Features Figure 7. Steroids Features Figure 8. Others Features Figure 9. Global Neuropathic Pain Drugs Market Share by Application: 2020 VS 2026 Figure 10. Hospital Pharmacies Case Studies Figure 11. Retail Pharmacies Case Studies Figure 12. Online Pharmacies Case Studies Figure 13. Neuropathic Pain Drugs Report Years Considered Figure 14. Global Neuropathic Pain Drugs Market Size YoY Growth 2015-2026 (US$ Million) Figure 15. Global Neuropathic Pain Drugs Market Share by Regions: 2020 VS 2026 Figure 16. Global Neuropathic Pain Drugs Market Share by Regions (2021-2026) Figure 17. Porter's Five Forces Analysis Figure 18. Global Neuropathic Pain Drugs Market Share by Players in 2019 Figure 19. Global Top Neuropathic Pain Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuropathic Pain Drugs as of 2019 Figure 20. The Top 10 and 5 Players Market Share by Neuropathic Pain Drugs Revenue in 2019 Figure 21. North America Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Europe Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 23. China Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Japan Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 25. Southeast Asia Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 26. India Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 27. Central & South America Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 28. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 29. Pfizer Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 30. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018 Figure 31. Johnson & Johnson Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 32. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 33. Sanofi Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 34. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018 Figure 35. GlaxoSmithKline Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 36. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018 Figure 37. Eli Lilly Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 38. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018 Figure 39. Bristol-Myers Squibb Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 40. Biogen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 41. Biogen Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 42. Baxter Healthcare Total Revenue (US$ Million): 2019 Compared with 2018 Figure 43. Baxter Healthcare Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 44. Depomed Total Revenue (US$ Million): 2019 Compared with 2018 Figure 45. Depomed Revenue Growth Rate in Neuropathic Pain Drugs Business (2015-2020) Figure 46. Bottom-up and Top-down Approaches for This Report Figure 47. Data Triangulation Figure 48. Key Executives Interviewed

Pfizer Johnson & Johnson Sanofi GlaxoSmithKline Eli Lilly Bristol-Myers Squibb Biogen Baxter Healthcare Depomed